How Does Efruxifermin Work? Mechanism of Action, Per the Research

What efruxifermin is, in pharmacological terms

Efruxifermin (often abbreviated EFX) is an investigational biologic rather than a small molecule. A 2023 pharmacology review of the agent described it as a bivalent Fc-FGF21 fusion protein engineered to reproduce the biological activity of native human fibroblast growth factor 21 while resisting the rapid clearance that limits the native hormone, and positioned it as a candidate for fibrotic and cirrhotic non-alcoholic steatohepatitis (PMID 37376813). The fusion design is the reason the compound has been administered on a weekly schedule in clinical research: the phase 2b HARMONY trial evaluated once-weekly subcutaneous efruxifermin at 28 mg and 50 mg versus placebo over 24 weeks in adults with non-alcoholic steatohepatitis and fibrosis (PMID 37802088).

Because efruxifermin is a protein hormone analog, "mechanism of action" means two separate questions. First, which receptors does it bind and what signalling follows? Second, how do those signalling events translate into the metabolic and histological changes that trials measured? The first question is reasonably well defined by FGF21 biology; the second is where established mechanism shades into proposed mechanism.

Receptor targets and the β-Klotho requirement

Native FGF21 is an endocrine member of the fibroblast growth factor family. Unlike classical FGFs, it has low affinity for heparan sulphate and instead depends on a membrane co-receptor, β-Klotho, to form a productive complex with FGF receptors of the "c" splice class (FGFR1c, FGFR2c, FGFR3c). This co-receptor requirement is what gives FGF21 pharmacology its tissue selectivity: signalling occurs predominantly where β-Klotho is expressed, chiefly white and brown adipose tissue, liver, pancreas and parts of the central nervous system. The review of efruxifermin framed the molecule as an FGF21 analog designed to engage this same endocrine pathway (PMID 37376813), and a systematic review of emerging therapies for fatty liver disease grouped FGF21 analogs as a distinct mechanistic class alongside thyroid hormone receptor-β agonists and incretin-based agents (PMID 37701920).

Downstream of receptor engagement, FGF21 signalling is canonical receptor tyrosine kinase signalling: FGFR dimerisation, substrate phosphorylation (FRS2α), and activation of the RAS-MAPK/ERK pathway, with secondary effects on transcriptional programmes governing lipid handling and glucose uptake. Much of this intracellular detail comes from cell-based and animal FGF21 work rather than from human efruxifermin studies, and readers should treat it as background biology for the class rather than as something measured in the clinical trials cited on this page.

Established versus proposed mechanism

Reasonably established

• It is an FGF21 mimetic with extended exposure. The Fc fusion architecture and the intent to mimic native FGF21 were described in the agent-specific review (PMID 37376813).
• Weekly subcutaneous exposure produces measurable metabolic change in humans. HARMONY reported improvements in non-invasive markers of liver injury and in lipid and glycaemic parameters alongside its histology endpoints over 24 weeks (PMID 37802088).
• Liver fat falls. A randomised phase 2 study in participants with NASH/MASH and type 2 diabetes who were already on a GLP-1 receptor agonist reported greater reductions in hepatic fat fraction measured by MRI-PDFF with added efruxifermin than with placebo (PMID 38447814).

Proposed or inferred

• Adipose-first signalling. The dominant hypothesis is that β-Klotho-rich adipose tissue is the primary site of action, with hepatic benefit following from reduced lipid flux and altered adipokine signalling. Human trials of efruxifermin have measured downstream readouts rather than directly demonstrating the tissue sequence (PMID 37376813).
• Anti-fibrotic effect as an indirect consequence. Reviews of liver fibrosis biology describe activated hepatic stellate cells as the central effector of extracellular matrix deposition and as the key target of anti-fibrotic strategies (PMID 40785947). Whether efruxifermin acts on stellate cells directly, or whether fibrosis endpoints in trials reflect the removal of lipotoxic and inflammatory drivers, is not resolved by the clinical studies cited here.
• Cardiometabolic spillover. A review of fatty liver disease management in the context of cardiovascular disease emphasised that hepatic steatosis sits within a broader insulin-resistant, atherogenic-dyslipidaemic phenotype (PMID 35507280), which is the rationale for interpreting lipid changes seen with FGF21 analogs as mechanistically connected rather than incidental.

Downstream physiology as described in the literature

The pathway most often invoked for FGF21 analogs runs through adipose tissue. Receptor engagement on adipocytes is proposed to increase glucose uptake, raise adiponectin secretion, and reduce lipolysis and the delivery of free fatty acids to the liver. In the liver, lower substrate load plus altered transcriptional control of de novo lipogenesis and fatty acid oxidation is proposed to reduce triglyceride accumulation and lipotoxic intermediates, which in turn reduces hepatocyte stress, inflammatory signalling and the stimulus for stellate cell activation.

What the human studies measured sits at the ends of that chain rather than in its middle. The phase 2b trial in non-cirrhotic disease reported fibrosis and steatohepatitis histology endpoints at 24 weeks together with non-invasive marker changes (PMID 37802088), and a phase 2a trial in compensated NASH cirrhosis reported changes in markers of liver injury and fibrosis with once-weekly efruxifermin versus placebo in that more advanced population (PMID 36644237). Neither design can show which tissue acted first.

How this mechanism differs from other MASH drug classes

Mechanistic contrast helps clarify what an FGF21 analog is and is not. Incretin-based agents act through GLP-1 and, in some molecules, glucagon receptors: a randomised, double-blind, placebo-controlled study of pemvidutide, a GLP-1/glucagon dual receptor agonist, reported reductions in liver fat content in participants with metabolic dysfunction-associated steatotic liver disease (PMID 39002641), and a 24-week randomised controlled trial of the same agent likewise reported hepatic fat and weight-related outcomes (PMID 41113119). Those pathways work substantially through appetite, energy intake and body weight. By contrast, the FGF21 route is generally framed as a direct metabolic-signalling intervention on adipose and hepatic lipid handling.

Indirect comparisons have been attempted. A systematic review and network meta-analysis of pharmacological therapies in metabolic dysfunction-associated steatohepatitis ranked agents for fibrosis regression and steatohepatitis resolution across trials (PMID 39903735), and a separate network meta-analysis compared resmetirom, a thyroid hormone receptor-β agonist, with efruxifermin across randomised controlled trials (PMID 41947319). Network meta-analyses pool across heterogeneous populations and endpoints, and the researchers who perform them typically flag that indirect comparisons do not substitute for head-to-head trials.

Tolerability and Mechanism-Linked Effects: What Studies Report

Some reported adverse events plausibly trace back to the same receptor biology. Gastrointestinal events, diarrhoea, nausea and increased appetite among them, were the most commonly reported treatment-emergent events in the phase 2b trial of once-weekly efruxifermin, and the study described most events as mild to moderate (PMID 37802088). The phase 2a trial in compensated NASH cirrhosis similarly reported gastrointestinal events as the most frequent adverse events in that population (PMID 36644237). In the combination study with a GLP-1 receptor agonist, researchers reported on tolerability when efruxifermin was added to existing incretin therapy in participants with type 2 diabetes (PMID 38447814). A 2025 analysis of safety considerations for forthcoming non-cirrhotic metabolic steatohepatitis treatments discussed how tolerability profiles differ by drug class and how those differences may shape clinical decision-making (PMID 40815181).

What the mechanism does not yet explain

1. Tissue attribution. No cited human trial isolates adipose from hepatic contributions to the observed changes.
2. Durability. The trials summarised here ran over weeks to months; the phase 2b trial's histology endpoint was assessed at 24 weeks (PMID 37802088), which cannot speak to long-term pathway adaptation.
3. Fibrosis causality. Reviews describe stellate cell activation as the proximate fibrogenic step (PMID 40785947), but direct evidence that efruxifermin modulates those cells in human liver is not established by the clinical papers cited here.
4. Comparative mechanism. Indirect comparisons against other mechanisms exist (PMID 41947319), but mechanism ranking and efficacy ranking are not the same thing.

Regulatory and research status

Efruxifermin has been studied in randomised phase 2a and phase 2b settings, and the literature consistently describes it as investigational rather than an approved therapy; the 2023 agent review used exactly that framing (PMID 37376813). Reviews of the broader treatment landscape place FGF21 analogs among emerging options still being defined by trial data (PMID 37701920). A more general overview of efruxifermin research, including trial design and endpoints, is covered separately in PeptideU's efruxifermin learn entry.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition, medication or investigational therapy. Nothing here describes how any compound should be used.

References

• Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial (The Lancet Gastroenterology & Hepatology, 2023)
• Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study (Clinical Gastroenterology and Hepatology, 2025)
• A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis (JHEP Reports, 2023)
• Efruxifermin, an investigational treatment for fibrotic or cirrhotic nonalcoholic steatohepatitis (NASH) (Expert Opinion on Investigational Drugs, 2023)
• Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis (Hepatology, 2025)
• Comparative Efficacy and Safety of Resmetirom and Efruxifermin for Metabolic Dysfunction-Associated Steatohepatitis: A Network Meta-Analysis of Randomized Controlled Trials (Endocrinology, Diabetes & Metabolism, 2026)
• Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study (Journal of Hepatology, 2025)
• Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial (JHEP Reports, 2025)
• Safety Choice Drivers of the Coming Treatment Options for Non-Cirrhotic Metabolic Steatohepatitis (Liver International, 2025)
• Nanomedicines in the Treatment of Liver Fibrosis: A Review (International Journal of Nanomedicine, 2025)
• Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease (Current Atherosclerosis Reports, 2022)
• Emerging therapeutic options for non-alcoholic fatty liver disease: A systematic review (World Journal of Hepatology, 2023)